WARREN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful ...
Forbes contributors publish independent expert analyses and insights. Kim Elsesser covers issues that impact women in the workplace. Organizations regularly use non-disclosure agreements (NDAs) to ...
NDA 1 2026 exam is scheduled for April 12, 2026. With only a few months left, candidates should start preparing for the exam.
The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for ...
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
CEO Rick Stewart stated that "Achieve is on track to submit the NDA for cytisinicline next month." He emphasized that "all internal resources are now focused on a successful NDA submission, acceptance ...
TOKUSHIMA, Japan--(BUSINESS WIRE)--150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, ...
Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback